ArticleThe EMBO journal2026
A fibroblast-like endothelial cell state promotes atherosclerosis via C/EBPβ-activated TGF-β signaling.
Article in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- USP5 Stabilizes TGFBR1 to Drive Vascular Smooth Muscle Cell Senescence and Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Endothelial cell (EC) dysfunction is a critical driver of chronic vascular inflammation and atherosclerosis. However, the molecular details of EC state dynamics during vascular disease progression remain ill-defined. Here, we used in-depth single-cell RNA sequencing to map transcriptional landscapes and molecular signatures of EC phenotypic plasticity during atherosclerosis in the mouse arota. This analysis identified a unique fibroblast-like EC population in atherosclerotic blood vessels, characterized by high expression of endothelial activation markers and extracellular matrix (ECM) remodeling, which increased with disease severity. Pseudotime trajectory analysis revealed that these fibroblast-like ECs represent terminal states of endothelial-mesenchymal transition (EndMT) during atherosclerosis. Further, the transcription factor C/EBPβ was identified as prominent driver of this phenotype transition as evidenced in vivo and in vitro. Mechanistically, inflammatory cytokines induce C/EBPβ, triggering TGF-β signaling and subsequent regulation of downstream genes via upregulation of TGF-β receptor type I (TGFBR1) through direct interaction with its promoter. Endothelial overexpression of C/EBPβ in vivo exacerbated atherosclerotic plaques, increased vascular inflammation, and elevated endothelial TGFBR1 levels. These findings highlight endothelial C/EBPβ as a novel regulator of TGF-β signaling and pathological fibroblast-like EC phenotypes during atherosclerosis, linking cytokine-driven inflammation with TGF-β-mediated endothelial dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.